• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login
Search
Generic filters

AbCellera

Member Profile

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Antibodies
  • Artificial Intelligence
  • Autoimmune Diseases
  • Cardiovascular Disease
  • Drug Discovery
  • Infectious Diseases
  • Inflammatory Diseases
  • Neurological Diseases
  • Oncology
  • Ophthalmology
  • Therapeutics
This member is looking for Expanding Operations in BC
Description of Services
Therapeutic antibody discovery and partnerships.
Company Stage Public Company
Stock Ticker ABCL - NASDAQ
Pitch Deck

We are working On:

AbCellera’s unique business model brings our operating system to the industry through partnerships. Over the past six years, we have partnered on over 100 therapeutic antibody discovery programs, working with companies that span the gamut from early-stage biotech to some of the world’s largest and most enabled biopharmaceutical companies. By partnering with AbCellera, these groups can move more quickly, reduce costs, and tackle some of the toughest problems in antibody discovery. Typically, our partners come to us when they have identified the disease target. We then apply our technology to discover high quality potent antibodies that are suitable for development, and we return these antibodies to our partners for final preclinical development and clinical testing. This includes partnerships in oncology, inflammation, cardiovascular disease, pain, neurodegeneration and many more. We structure our agreements in a way that aligns our interests with the success of our partners and ultimately with the patients they serve. Our partnership agreements include technical access fees and research payments, clinical and commercial milestones and royalties on net sales of approved products.

Member Profile

Biotechnology, Therapeutics

AbCellera

Gold Sponsor

AbCellera logo black text green shape
  • Website www.abcellera.com
  • Phone +1 (604) 559 9005
  • Email info@abcellera.com
  • Address
    2215 Yukon Street
    Vancouver, BC
    V5Y 0A1
  • Leadership Contact
    Carl Hansen, Director & CEO
    Follow us:
  • Twitter
  • LinkedIn
  • Instagram
  • News
  • Jobs

August 3, 2022

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

July 27, 2022

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

June 29, 2022

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

November 24, 2021

Visionary Biotech Player Carl Hansen of AbCellera Named Canada’s EY Entrepreneur Of The Year® 2021

November 2, 2021

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

No current content.

  • Twitter
  • Linkedin
Tweets by AbCellera
Connect with us LinkedIn

© 2022 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us